Silo Pharma, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

27 Mar 2026

SILO

10-K: Silo Pharma Navigates Biopharma & Crypto, Reports $4.2M Loss

Silo Pharma, a developmental-stage biopharmaceutical and cryptocurrency company, reported a net loss of $4.2 million for 2025 while advancing its drug pipeline and managing a volatile digital asset treasury.

NASDAQ

28 Mar 2025

SILO

Silo Pharma, INC

10-K: Silo Pharma Reports Progress on PTSD and Alzheimer's Therapeutics in Annual Filing

Silo Pharma's 10-K filing highlights advancements in its drug development pipeline, including SPC-15 for PTSD and SPC-14 for Alzheimer's, while addressing financial and operational risks.

NASDAQ

25 Mar 2024

SILO

Silo Pharma, INC

10-K: Silo Pharma Details Securities and Financials in Annual 10-K Filing

Silo Pharma's annual 10-K filing provides a comprehensive overview of its securities, financial condition, and ongoing research and development programs.